AFT hits US approval target, triggers cash

Managing director Hartley Atkinson said Maxigesic was an effective alternative for the US$700 million of IV paracetamol sold each year. (Photo: supplied).

Dan Brunskill

Mon, 01 Nov 2021

The United States medical regulator has accepted an application for AFT Pharmaceuticals’ patented pain relief medicine, which if approved would open up a more than US$300 million market.The US Food and Drug Administration has formally received the application for Maxigesic IV, an intravenous form of AFT’s painkiller, which was filed in August this year.Filing with the FDA triggers milestone payments worth US$3.6m under a licensing deal with US partner Hikma Pharmaceuticals. This will be recognised in the first half of the current fi...

Subscribe to BusinessDesk

Stay informed on business, government and financial developments across New Zealand.

Deeply researched, twice-edited and fact-checked news
Annual subscribers also receive a complimentary subscription to The Wall Street Journal
Personalised email news alerts, plus gift up to 5 stories a month to non-subscribers

You can cancel anytime with two clicks, an email or a phone call.
Find out more.

We are serious about journalism.

Name {{ registerForm.errors.get('name') }}

Email address {{ registerForm.errors.get('email') }}

Phone Number {{ registerForm.errors.get('phone') }}

Job Title {{ registerForm.errors.get('title') }}

Password Minimum password length of 8 characters.
Require at least one upper and lowercase, numeric, and special character. {{ registerForm.errors.get('password') }}

Repeat password {{ registerForm.errors.get('password_confirmation') }}

We had trouble validating your card. It's possible your card provider is preventing us from charging the card. Please contact your card provider or customer support.

Credit Card

Cardholder's name

{{ __(plans[index].name) | capitalize }} {{ plans[index].attributes.old_price | currency }} {{ plans[index].price | currency }}

All subscriptions auto renew but are easy to cancel.

I Accept The Terms Of Service

{{ registerForm.errors.get('terms') }}

Tax: {{ taxAmount(selectedPlan) | currency }}

Total Price Including Tax: {{ priceWithTax(selectedPlan) | currency }} {{ selectedPlan.type == 'user' && spark.chargesUsersPerSeat ? '/ '+ spark.seatName : '' }} {{ selectedPlan.type == 'user' && spark.chargesUsersPerTeam ? '/ '+ __('teams.team') : '' }} / {{ __(selectedPlan.interval) | capitalize }}

Travel

Airport hotels are evolving beyond layover necessities

The staid, cheap, bed-for-a-night abodes no longer dominate airport hotels.

The Washington Post 5:00am

Bloomberg Opinion

US bonds have never been risk-free, and never will be

It will still be a low-risk asset and in high demand.

Bloomberg 26 Apr 2025

US bonds have never been risk-free, and never will be

World

Morocco volunteers on Sahara clean-up mission

Some 50 people, gloved and equipped with rubbish bags, toiled away for five hours.

AFP 26 Apr 2025

Morocco volunteers on Sahara clean-up mission

Sponsored

“Not an invisible footprint”: Why technology supply chains need optimising

Outdated hardware is a supply chain and cost risk.

Datacom

Sponsored

Bayleys Total Property Issue 3 out now

Backed by Bayleys’ national strength and global reach

Bayleys

More Markets

Markets Market Close

NZ sharemarket up 0.5% ahead of long weekend

Pacific Edge's share price fell 7.32%.

Tom Raynel 24 Apr 2025

Markets

Pacific Edge suffers another setback in US

Shares in cancer diagnostics company Pacific Edge are down 2.44% to $0.120 after another setback in the US market.The US District Court for the Middle District of Pennsylvania has determined that it does not have jurisdiction to review a Local Coverage Determination (LCD) that co...

Staff reporters 24 Apr 2025